Pharming Group N.V. PHARM

AMS: PHARM | ISIN: NL0010391025 14/09/2026

0,935 EUR (+0,91%)

(+0,91%) 14/09/2026

Grafiek Pharming Group N.V.

Grafiek Pharming Group N.V.

1 dag1d 0,91%
1 week1w -3,65%
1 maand1m -8,65%
3 maanden3m -15,73%
6 maanden6m -30,86%
1 jaar1j -22,44%
5 jaar5j 13,11%

Adviezen van analisten

Koersdoel

2,16 EUR

+131,18%

Consensus

Kopen

Verdeling adviezen

Pharming Group N.V. in het nieuws

Toon enkel gratis nieuws

11 september 2026 · FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S. · Persbericht

9 september 2026 · Pharming Group to participate in September investor conferences · Persbericht

13 augustus 2026 · Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older · Persbericht

7 augustus 2026 · Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky · Persbericht

4 augustus 2026 · Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference · Persbericht

3 augustus 2026 · PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group · Persbericht

31 juli 2026 · Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR) · Persbericht

30 juli 2026 · Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use · Persbericht

16 juli 2026 · Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30 · Persbericht

4 juni 2026 · Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS · Persbericht

Profiel Pharming Group N.V.

Gezondheidstechnologie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe